Researchers have developed a two-step approach using whole exome sequencing to zero in on genes and pathways that predict whether cancer patients will respond to immunotherapy.
A phase II clinical trial of poziotinib for non-small cell lung cancer with epidermal growth factor receptor exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may impact future clinical trials for EGFR exon 20 targeted therapies.
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX plus hypofractionated radiotherapy, researchers from MD Anderson Cancer Center found.
FDA approved crizotinib (Xalkori) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase-positive myofibroblastic tumors.
Karen E. Knudsen has spent the past year bringing the American Cancer Society into the 21st century.
Some things are known to grow well in Kansas. Some things aren’t. Over the past 18 years, Roy Jensen has been told time and again that it made no sense to even try to grow an NCI-designated Comprehensive Cancer Center in Kansas. Yet, he did the only thing he could. Persist. Stubbornly. The University of... […]
The House Appropriations Committee approved a $2.5 billion increase for NIH in fiscal year 2023, as part of a June 30 markup of the Labor, Health and Human Services, Education, and Related Agencies spending bill.
A team of researchers at Fox Chase Cancer Center was awarded a Department of Defense Prostate Cancer Health Disparity Research Award for New Investigators.
Fred Hutchinson Cancer Center announced the 10 recipients of the 2022 Dr. Eddie Méndez award. The awards are named after a physician-scientist at Fred Hutch who focused on supporting early-career scientists underrepresented in science.
Noel Alaka was named vice president of life sciences COTA Inc.
